Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo
Sponsor: Bayer
Listed as NCT00056459, this PHASE3 trial focuses on Colonic Neoplasms and Colorectal Neoplasms and remains completed. Sponsored by Bayer, it has been updated 10 times since 2003, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .